Sequenom
Clinical trials sponsored by Sequenom, explained in plain language.
A molecular diagnostics company known for prenatal testing, now part of Labcorp.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New blood test aims to sharpen prostate cancer detection Results expected Mar 2027 (estimated)
- Simple blood test may spot preeclampsia risk before symptoms appear Results expected Jun 2027 (estimated)
-
A simple blood draw could one day detect down syndrome in pregnancy
Diagnosis Recruiting nowResearchers are collecting blood samples from pregnant women at higher risk of having a baby with a chromosomal condition. The goal is to develop a noninvasive prenatal test that looks at cell-free DNA in the mother's blood to detect Down syndrome. Participants give blood between…
Sponsor: Sequenom, Inc. • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
New blood test aims to sharpen prostate cancer detection
Diagnosis Recruiting nowThis study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be co…
Sponsor: Sequenom, Inc. • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Simple blood test may spot preeclampsia risk before symptoms appear
Diagnosis Recruiting nowThis study aims to improve early detection of preeclampsia, a dangerous pregnancy condition. Researchers will collect blood samples from over 6,500 pregnant women between 11-14 weeks of pregnancy and compare the results with pregnancy outcomes. The goal is to see how well a new b…
Sponsor: Sequenom, Inc. • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC